Intensive Care Medicine

, Volume 40, Issue 10, pp 1509–1517 | Cite as

Effect of the use of low and high potency statins and sepsis outcomes

  • Shu-Yu Ou
  • Hsi Chu
  • Pei-Wen Chao
  • Shuo-Ming Ou
  • Yi-Jung Lee
  • Shu-Chen Kuo
  • Szu-Yuan Li
  • Chia-Jen Shih
  • Yung-Tai Chen
Original

Abstract

Introduction

Although statins have been shown to have cholesterol-lowering effects, their pleiotropic benefits on sepsis remain a matter of debate. In addition, the influence of statin potency on sepsis-related mortality has never been explored. The aim of our study was to determine the sepsis outcomes of low- and high-potency statin users and non-users.

Methods

This nationwide, population-based, propensity score-matched analysis used data from the linked administrative databases of Taiwan’s National Health Insurance program. Patients were hospitalized for sepsis between 2000 and 2010. All-cause mortality and major adverse consequences of sepsis, such as in-hospital death, intensive care unit admission, shock events, and the use of mechanical ventilation, were assessed. Patients were divided into high-potency statin users (at least 10 mg rosuvastatin, at least 20 mg atorvastatin, or at least 40 mg simvastatin), low-potency statin users (all other statin treatments), and non-users.

Results

A propensity score-matched cohort of 27,792 statin users and 27,792 non-users was included. Of 27,792 statin users, 9,785 (35.2 %) were treated with high-potency statins and 18,007 (64.8 %) were treated with low-potency statins. The 1-year mortality risk was significantly lower among both low-potency [adjusted hazard ratio (aHR) 0.89, 95 % confidence interval (CI) 0.85–0.93] and high-potency (aHR 0.80, 95 % CI 0.75–0.86) statin users compared with non-users. The risks of mortality and adverse consequences of sepsis were lower among high-potency than among low-potency statin users.

Conclusions

High-potency statin use is associated with a lower risk of sepsis-related mortality compared with low-potency statin use.

Keywords

Statin Potency Sepsis Mortality National Health Insurance Research Database 

Notes

Conflicts of interest

All authors state that they have no conflicts of interest.

Supplementary material

134_2014_3418_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 33 kb)

References

  1. 1.
    Ballantyne CM, Raichlen JS, Cain VA (2008) Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (measuring effective reductions in cholesterol using rosuvastatin) trial. J Am Coll Cardiol 52:626–632PubMedCrossRefGoogle Scholar
  2. 2.
    Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213PubMedCrossRefGoogle Scholar
  3. 3.
    John S, Schneider MP, Delles C, Jacobi J, Schmieder RE (2005) Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 149:473PubMedCrossRefGoogle Scholar
  4. 4.
    Lahera V, Goicoechea M, de Vinuesa SG, Miana M, De las Heras N, Cachofeiro V, Luno J (2007) Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 14:243–248PubMedCrossRefGoogle Scholar
  5. 5.
    Skaletz-Rorowski A, Walsh K (2003) Statin therapy and angiogenesis. Curr Opin Lipidol 14:599–603PubMedCrossRefGoogle Scholar
  6. 6.
    Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, Shin EK (2003) Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 88:77–82PubMedCrossRefGoogle Scholar
  7. 7.
    Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T (2013) Host innate immune responses to sepsis. Virulence 5(1):36–44PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169:1658–1667PubMedCrossRefGoogle Scholar
  9. 9.
    Dobesh PP, Olsen KM (2014) Statins role in the prevention and treatment of sepsis. Pharmacol Res doi: 10.1016/j.phrs.2014.04.010
  10. 10.
    Antonelli M, Bonten M, Chastre J, Citerio G, Conti G, Curtis JR, De Backer D, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2012) Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulation. Intensive Care Med 38:345–358PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043–1046PubMedGoogle Scholar
  12. 12.
    Kopterides P, Falagas ME (2009) Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15:325–334PubMedCrossRefGoogle Scholar
  13. 13.
    Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ (2007) Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 27:1619–1626PubMedCrossRefGoogle Scholar
  14. 14.
    Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts, Venkatesh B, Group AN-SI-ACT (2013) A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 187:743–750PubMedCrossRefGoogle Scholar
  15. 15.
    Yang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, Wu CC (2007) Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 25:494–501PubMedCrossRefGoogle Scholar
  16. 16.
    Fernandez R, De Pedro VJ, Artigas A (2006) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 32:160–164PubMedCrossRefGoogle Scholar
  17. 17.
    Leung S, Pokharel R, Gong MN (2012) Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Crit Care Med 40:1064–1071PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Patel JM, Thickett DR, Gao F, Sapey E (2013) Statins for sepsis: distinguishing signal from the noise when designing clinical trials. Am J Respir Crit Care Med 188:874PubMedCrossRefGoogle Scholar
  19. 19.
    Hollis S, Campbell F (1999) What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319:670–674PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P, Canadian Network for Observational Drug Effect Studies (2013) Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 346:f880PubMedCrossRefGoogle Scholar
  21. 21.
    WHO Collaborating Center for Drugs Statistics Methodology (2003) ATC index with DDDs 2003. WHO, OsloGoogle Scholar
  22. 22.
    Chang WP, Liu ME, Chang WC, Yang AC, Ku YC, Pai JT, Huang HL, Tsai SJ (2013) Sleep apnea and the risk of dementia: a population-based 5-year follow-up study in Taiwan. PLoS One 8:e78655PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRefGoogle Scholar
  24. 24.
    Rubin DB, Thomas N (1996) Matching using estimated propensity scores: relating theory to practice. Biometrics 52:249–264PubMedCrossRefGoogle Scholar
  25. 25.
    Austin PC (2008) A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27:2037–2049PubMedCrossRefGoogle Scholar
  26. 26.
    Brealey DA, Singer M, Terblanche M (2011) Potential metabolic consequences of statins in sepsis. Crit Care Med 39:1514–1520PubMedCrossRefGoogle Scholar
  27. 27.
    Antonelli M, Bonten M, Chastre J, Citerio G, Conti G, Curtis JR, De Backer D, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2012) Year in review in Intensive Care Medicine 2011: I. nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals. Intensive Care Med 38:192–209PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Martin CP, Talbert RL, Burgess DS, Peters JI (2007) Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27:20–26PubMedCrossRefGoogle Scholar
  29. 29.
    Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM (2009) Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29:621–630PubMedCrossRefGoogle Scholar
  30. 30.
    Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, Goutorbe P, Lefrant JY, Wiramus S, Jung B, Perbet S, Hernu R, Nau A, Baldesi O, Allardet-Servent J, Baumstarck K, Jouve E, Moussa M, Hraiech S, Guervilly C, Forel JM, Group S-VS (2013) Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 310:1692–1700PubMedCrossRefGoogle Scholar
  31. 31.
    Antonelli M, Bonten M, Chastre J, Citerio G, Conti G, Curtis JR, De Backer D, Hedenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore SM, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2012) Year in review in Intensive Care Medicine 2011: III. ARDS and ECMO, weaning, mechanical ventilation, noninvasive ventilation, pediatrics and miscellanea. Intensive Care Med 38:542–556PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Burke JP (2003) Infection control—a problem for patient safety. N Engl J Med 348:651–656PubMedCrossRefGoogle Scholar
  33. 33.
    Liu CY, Liao CH, Chen YC, Chang SC (2010) Changing epidemiology of nosocomial bloodstream infections in 11 teaching hospitals in Taiwan between 1993 and 2006. J Microbiol Immunol Infect 43:416–429PubMedCrossRefGoogle Scholar
  34. 34.
    Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885PubMedCrossRefGoogle Scholar
  35. 35.
    Fuller BM, Gajera M, Schorr C, Gerber D, Dellinger RP, Zanotti S (2012) The association of prior statin use in septic shock treated with early goal directed therapy. Eur J Emerg Med 19:226–230PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004) Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47–56PubMedCrossRefGoogle Scholar
  37. 37.
    Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B (2011) Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 183:774–781PubMedCrossRefGoogle Scholar
  38. 38.
    Bruyere R, Vigneron C, Prin S, Pechinot A, Quenot JP, Aho S, Papazian L, Charles PE (2014) Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study. Crit Care 18:R83PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Loppnow H, Zhang L, Buerke M, Lautenschlager M, Chen L, Frister A, Schlitt A, Luther T, Song N, Hofmann B, Rose-John S, Silber RE, Muller-Werdan U, Werdan K (2011) Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med 15:994–1004PubMedCrossRefGoogle Scholar
  40. 40.
    Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399–424CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2014

Authors and Affiliations

  • Shu-Yu Ou
    • 1
  • Hsi Chu
    • 2
    • 3
    • 4
  • Pei-Wen Chao
    • 5
  • Shuo-Ming Ou
    • 2
    • 6
    • 7
  • Yi-Jung Lee
    • 2
    • 8
  • Shu-Chen Kuo
    • 2
    • 9
    • 10
  • Szu-Yuan Li
    • 2
    • 6
    • 7
  • Chia-Jen Shih
    • 2
    • 11
  • Yung-Tai Chen
    • 2
    • 12
    • 13
  1. 1.School of Medicine, Kaohsiung Medical UniversityKaohsiungTaiwan
  2. 2.School of Medicine, National Yang-Ming UniversityTaipeiTaiwan
  3. 3.Department of ChestTaipei City HospitalTaipeiTaiwan
  4. 4.School of Jen-Teh Junior College of Medicine, Nursing and ManagementMiaoli CountyTaiwan
  5. 5.Department of AnesthesiologyWan Fang Hospital, Taipei Medical UniversityTaipeiTaiwan
  6. 6.Division of Nephrology, Department of MedicineTaipei Veterans General HospitalTaipeiTaiwan
  7. 7.Institute of Clinical Medicine, National Yang-Ming UniversityTaipeiTaiwan
  8. 8.Department of NeurologyNeurological Institute, Taipei Veterans General HospitalTaipeiTaiwan
  9. 9.National Institute of Infectious Diseases and Vaccinology, National Health, Research InstitutesMiaoli CountyTaiwan
  10. 10.Division of Infectious DiseasesTaipei Veterans General HospitalTaipeiTaiwan
  11. 11.Department of MedicineTaipei Veterans General Hospital, Yuanshan BranchYilanTaiwan
  12. 12.Department of MedicineTaipei City Hospital, Heping Fuyou BranchTaipeiTaiwan
  13. 13.Department of NephrologyTaipei City Hospital Heping Fuyou BranchTaipeiTaiwan

Personalised recommendations